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INTRODUCTION: The expression of RNA and 
protein for a multitude of different phase 1 & 2 
xenobiotic metabolizing enzymes has been 
demonstrated both in ex vivo human skin and in in 
vitro tissue-engineered human skin equivalents by 
microarray and mass spectrometry techniques [1-
2]. The presence of these enzymes in the skin is of 
considerable importance for the pharmaceutical/ 
cosmetic industry as xenobiotic compounds 
delivered topically or systemically to the skin may 
be metabolized to produce active metabolites that 
may either be beneficial (release of active drugs 
from pro-drugs) or may cause toxicity or 
hypersensitivity. Here we use mathematical 
models, parameterised against in vitro 
experimental data, to inform the spatial distribution 
of metabolism in tissue-engineered skin samples. 
METHODS: A coupled system of partial 
differential equations was developed to describe 
the transport of parent compound and metabolites 
through a geometry representative of engineered 
skin equivalents (including corneum, granulosum, 
spinous, basal and dermal layers, with a fluid pool 
underneath, as used in the culture set-up). 
Diffusion and metabolism were defined based on 
literature values, and were specific to each layer 
[3-5]. The model was solved using COMSOL 
Multiphysics (a finite elements package), subject 
to boundary conditions that mimic the typical in 
vitro setup (for example, prescribed concentration 
of parent compound on the upper corneum surface, 
representative of topical delivery). 
RESULTS: The model predicts spatial 
heterogeneity in the parent compound and 
metabolite concentrations within the skin (see Fig. 
1). The parent compound concentration is highest 
at the upper corneum surface where it is delivered, 
and decays to a minimum within the basal cells at 
the bottom of the epithelium, as a consequence of 
cellular metabolism. The compound also diffuses 
through the extra-cellular spaces into the dermis, 
which consequently has a slightly higher 
concentration than the basal and lower spinous cell 
layers. This spatial distribution is mirrored by the 
metabolite, which is lowest in corneum/ 
granulosum/ dermal layers, and highest within the 
spinous cells. In both cases, intra- versus extra-
cellular transport routes are easily identifiable, and 
the patterning of cells within the spinous layer is a 
strong determinant of the spatial distributions of 
parent compound and metabolite.  
 
Fig. 1: Mathematical model predictions of the 
spatial distribution of parent compound (left) and 
metabolite (right) concentrations (both mol/m3); 
parent compound delivered topically on the upper 
corneum surface with results shown after 10 hours. 
Physical dimensions measured in metres. 
DISCUSSION & CONCLUSIONS: The 
mathematical model, parameterised by literature 
diffusion and metabolism parameters, was able to 
predict the spatial distribution of parent compound 
and metabolite within in vitro skin equivalents. 
This complete spatial information is particularly 
challenging to extract using a purely experimental 
approach. The model is generic, and next will be 
used to explore alternative delivery routes (e.g. 
systemic delivery of parent compound through the 
vasculature), and human skin geometries. 
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